StockpollyBeta
Get App
Popularity #4,245
PMN · NASDAQ · Biotechnology

ProMIS Neurosciences (PMN)

Develops EpiSelect-discovered antibodies for protein-misfolding neurodegenerative disorders.

$13.28
vs last close−0.30 (−2.21%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
3443467101211912
Research & development12223459109710
122122212123
General & administrative102120212023
Operating income−3−4−4−3−4−6−7−10−12−11−9−12
0000146000001
Interest expense000000000000
Other non-operating income0000−14000000−1
Income before tax−2−4−4−390−7−10−12−11−8−12
Net income from continuing operations−2−4−4−390−7−10−12−11−8−12
Net income−2−4−4−390−7−10−12−11−8−12
EPS, basic−$4.75−$4.57−$4.75−$3.25$7.75−$0.17−$5.25−$7.25−$8.27−$6.08−$1.26−$1.28
EPS, diluted−$4.75−$4.57−$4.75−$3.25$7.75−$0.17−$5.25−$7.25−$8.27−$6.08−$1.26−$1.28
Weighted average shares, basic011111111279
Weighted average shares, diluted011111111279
EBITDA−2−4−4−39−6−7−10−12−11−9−12
Depreciation & amortization000000000000
EBIT−2−4−4−39−6−7−10−12−11−9−12